维普期刊资源整合服务平台（V6.5）

39篇 您的检索式：作者名="Cremolini"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Caveolin‐1 is a novel regulator of K‐RAS ‐dependent migration in colon carcinogenesis显示文摘	Upal K. Basu Roy Rebecca S. Henkhaus Fotios Loupakis Chiara Cremolini Eugene W. Gerner Natalia A. Ignatenko	2013	Int J Cancer2013，，1：	2
2	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial显示文摘	Gianluca Masi Fotios Loupakis Lisa Salvatore Lorenzo Fornaro Chiara Cremolini Samanta Cupini Andrea Ciarlo Francesca Del Monte Enrico Cortesi Domenico Amoroso Cristina Granetto Gabriella Fontanini Elisa Sensi Cristiana Lupi Michele Andreuccetti Alfredo Fa	2010	Lancet Oncology2010，，9：	2
3	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label,phase 3 TRIBE study 显示文摘	Cremolini C Loupakis F Antoniotti C	2015	Lancet Oncol2015，16，13：	1
4	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab显示文摘	Loupakis F Cremolini C Yang D	2013	PLo S One2013，8，66：	1
5	Early tumour shrinkage as a prognostic factor and surrogate end - point in colorectal cancer: A systematic review and pooled - analysis显示文摘	Petrelli F Pietrantonio F Cremolini C	2015	Eur J Cancer2015，51，7：	1
6	KRAS codon61,146 and BRAF mutations predict resistance to cetu-ximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，4：	1
7	Clinical impact of anti - epidermal growth factor receptor monoclonal an- tibodies in first - line treatment of metastatic colorectal cancer显示文摘	LOUPAKIS F CREMOLINI C SALVATORE L	2012	Cancer2012，118，6：	1
8	FOLFOXIRI/bevacizum- ab (bey) versus FOLFIRI/bev as first-line treatment in unresect- able metastatic colorectal cancer (mCRC) patients (pts) : Results of the phase Ⅲ TRIBE trim by GONO group 显示文摘	Faocone A Cremolini C Masi G	2013	J Clin Oncol2013，，：	1
9	FOLFOXIRI/bevacizumab(bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts):Results of the phase Ⅲ TRIBE trial by GONO group显示文摘	Falcone A Cremolini C Gianluca M	2013	J Clin Oncol2013，31，15：	1
10	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 显示文摘	Loupakis F Cremolini C Masi G	2014	N EnglJ Med2014，371，17：	1
11	Predictors of benefit in colorectal cancer treated with cetuximab:are we getting 'Lost in TranslationAL'显示文摘	Cremolini C Loupakis F Ruzzo A	2010	J Clin Oncol2010，28，11：	1
12	KRAS codon 61,146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild - type metastatic colorectal cancer 显示文摘	Loupakis F Ruzzo A Cremolini C	2009	Br J Cancer2009，101，：	1
13	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer显示文摘	Loupakis F Cremolini C Salvatore L	2014	Eur J Cancer2014，50，：	1
14	First-line anti- EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and recta-analysis 显示文摘	Pietrantonio F Cremolini C Petrelli F	2015	Crit Rev Oncol Hematol2015，96，1：	1
15	Initial therapy with FOLFOXIRI and bevacizumab for metastatic eolorectal cancer显示文摘	LOUPAKIS F CREMOLINI C MASI G	2014	N Engl J Med2014，，：	1
16	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer显示文摘	Marta Schirripa Chiara Cremolini Fotios Loupakis Manfredi Morvillo Francesca Bergamo Federica Zoratto Lisa Salvatore Carlotta Antoniotti Federica Marmorino Elisa Sensi Cristiana Lupi Gabriella Fontanini Veronica De Gregorio Riccardo Giannini Fulvio Basolo	2015	Int. J. Cancer2015，，1：	1
17	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer显示文摘	LOUPAKIS F CREMOLINI C MASI G	2014	N Engl J Med2014，371，17：	1
18	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer显示文摘	Loupakis F Cremolini C Masi G	2014	N Engl J Med2014，371，17：	1
19	FOLFOXIRI/ bevacizumab(bev)versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer(mCRC)patients(pts):Results of the phase Ⅲ TRIBE trial by GONO group MD显示文摘	FALCONE A CREMOLINI C MASI G	2013	J Clin Oncol2013，31，15：	1
20	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 显示文摘	Loupakis F Cremolini C Masi G	2014	N Engl J Med2014，371，17：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示